Modified Rankin Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Modified rankin score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Modified Rankin Score Today - Breaking & Trending Today

IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

/PRNewswire/ IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative. ....

Wei Wang , United States , Equecabtagene Autoleucel , Jinhua Zhang , Lancet Regional Health , Drug Administration , China National Medical Products Administration , Investigational New Drug , Release Syndrome , Cell Associated Neurotoxicity Syndrome , Myasthenia Gravis Activities , Daily Living Score , Quantitative Myasthenia Gravis Score , Myasthenia Gravis Quality , Life Score , Modified Rankin Score , Tongji Hospital , Tongji Medical School , Huazhong University , New Drug Application , National Medical Products Administration , Iaso Bio ,

IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

SHANGHAI and NANJING, CHINA, and SAN JOSE, Calif., April 5, 2024 /PRNewswire/ IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to ....

Wei Wang , United States , Equecabtagene Autoleucel , Jinhua Zhang , Drug Administration , China National Medical Products Administration , Lancet Regional Health , Investigational New Drug , Release Syndrome , Cell Associated Neurotoxicity Syndrome , Myasthenia Gravis Activities , Daily Living Score , Quantitative Myasthenia Gravis Score , Myasthenia Gravis Quality , Life Score , Modified Rankin Score , Tongji Hospital , Tongji Medical School , Huazhong University , New Drug Application , National Medical Products Administration , Thailand Business ,

IASO Bio's Equecabtagene Autoleucel for Refractory Myasthenia Gravis (MG) Case Report Published in EMBO Molecular Medicine

/PRNewswire/ On February 26, 2024, the impactful international academic journal, EMBO Molecular Medicine, published the clinical data of the fully human. ....

Wei Wang , Equecabtagene Autoleucel , Demyelinating Polyneuropathy , China National Medical Products Administration , Huazhong University Of Science , Tongji Medical College , Acetylcholine Receptor , Lipoprotein Receptor Related Protein , Ryanodine Receptor , Tongji Hospital , Huazhong University , Release Syndrome , Cell Associated Neurotoxicity Syndrome , Myasthenia Gravis Activities , Daily Living Score , Quantitative Myasthenia Gravis Score , Myasthenia Gravis Quality , Life Score , Modified Rankin Score , Myasthenia Gravis , Immune Mediated Necrotizing Myelopathy , Chronic Inflammatory Demyelinating Polyneuropathy , New Drug Application , National Medical Products Administration ,

"Time is brain, so we must BEFAST: Improving stroke identification and " by Donna Jay, Richard Wheatley et al.

Objective: Shoalhaven District Memorial Hospital is a rural (MM3) secondary hospital which is over an hour travel time from the nearest tertiary centre. The objective of the present study was to pilot the implementation of the BEFAST (Balance, Eyes, Face, Arms, Speech and Time) stroke screening tool at the ED, and determine whether its usage improved timely stroke detection. Methods: During initial implementation and training (October–December 2019), triage nurses consulted with senior medical officers before activating stroke calls. Data were collected for the subsequent 24 months (January 2020–2022), and retrospective records for confirmed strokes during a 24-month period prior to BEFAST implementation (October 2017–2019) were also collected. The main outcome measures were triage category, CT scan result time, discharge destination, length of stay (LOS) and Modified Rankin Score (MRS). Results: After BEFAST implementation, patients (n = 268) were three times more likely to be t ....

Shoalhaven District Memorial Hospital , Modified Rankin Score , Cerebrovascular Accident , Emergency Service ,

Dual antiplatelet therapy is noninferior to alteplase for patients with minor nondisabling acute ischemic stroke – the ARAMIS trial

1. The ARAMIS trial revealed that the rate of favourable neurologic function at 90 days was 93.8% among patients assigned to dual antiplatelet therapy (DAPT) compared to those assigned to intravenous alteplase at 91.4%. 2. This study shows evidence that DAPT is noninferior (with a difference greater than the prespecified margin of -4.5%) to alteplase ....

Rating Level , Acute Mild Ischemic Stroke , Modified Rankin Score ,